Cargando…
Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)
BACKGROUND: Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, and half of episodes diagnosed are recurrences. The best and most cost-effective t...
Autores principales: | Murray, Macey L., Meadows, Jade, Doré, Caroline J., Copas, Andrew J., Haddow, Lewis J., Lacey, Charles, Jit, Mark, Soldan, Kate, Bennett, Kate, Tetlow, Michelle, Nathan, Mayura, Gilson, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220496/ https://www.ncbi.nlm.nih.gov/pubmed/30400777 http://dx.doi.org/10.1186/s12874-018-0581-z |
Ejemplares similares
-
Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
por: Hoyme, U B, et al.
Publicado: (2002) -
Imiquimod (Aldara cream).
por: Buck, H W
Publicado: (1998) -
Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies
por: Baker, David A., et al.
Publicado: (2011) -
Early Treatment with Imiquimod 5% Cream of Periungual Warts in Vietnam: The Poorer, the Better
por: Minh, Phuong Pham Thi, et al.
Publicado: (2019) -
Determinants of high-risk human papillomavirus infection in anogenital warts
por: Ozaydin-Yavuz, Goknur, et al.
Publicado: (2019)